5-year Follow-up of a Randomized Controlled Trial of Immediate versus Delayed Zoledronic Acid for Prevention of Bone Loss in Postmenopausal Women with Breast Cancer Starting Letrozole after Tamoxifen: N03CC (Alliance)

BACKGROUND: Postmenopausal women with breast cancer (BC) receiving aromatase inhibitors are at increased risk for bone loss. The current study was undertaken to determine whether upfront versus delayed treatment with zoledronic acid (ZA) impacted bone loss. This report describes the 5-year follow-up...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Wagner-Johnston, Nina D., Sloan, Jeff A., Liu, Heshan, Kearns, Ann E., Hines, Stephanie L., Puttabasavaiah, Suneetha, Dakhil, Shaker R., Lafky, Jacqueline M., Perez, Edith A., Loprinzi, Charles L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4512885/
https://ncbi.nlm.nih.gov/pubmed/25930719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29327
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados